Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers gave the antibody treatment to those with multidrug-resistant HIV along with an optimized antiretroviral regimen.
Fostemsavir offers HIV treatment hope to those with no other options.
HIV, anti-vaxxers, dengue fever and weak primary health care make the World Health Organization’s list of priorities.
A review of randomized controlled trials found that the main apparent benefit of such testing occurred among those with virologic failure.
The CDC has issued increasingly urgent warnings about the possible emergence of drug-resistant strains of the STI.
In a recent trial, the investigational entry inhibitor helped fully suppress HIV in a majority of those with multidrug-resistant virus.
An ongoing study is giving the regimen to those acutely infected with HIV, before waiting for results of resistance and other lab tests.
The goal is an inexpensive point-of-care test that quickly determines an individual’s best treatment options.
Tivicay (dolutegravir) is a next-generation integrase inhibitor.
Most of such drug resistance seen is to older drugs.
In an ongoing trial of people on failing antiretroviral regimens, the injectable PRO 140 reduced viral load considerably.
The Food and Drug Administration approves antibody treatment Trogarzo for multidrug-resistant HIV.
However, two similar cases have been reported in Australia.
U.K. public health officials have expressed great concern over this latest sign of evolution of the sexually transmitted infection.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.